In silico and in vitro pharmacogenetics: Aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor

Pharmacogenomics Journal

Volumn 11, Issue 1, 2011, Pages 15-24

  Zhang, X ^a   Liu, H H ^b   Weller, P ^a   Zheng, M ^b   Tao, W ^a   Wang, J ^a   Liao, G ^a   Monshouwer, M ^a   Peltz, G ^b  

^a Roche Palo Alto ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

aldehyde oxidase; inbred mouse strains; pharmacogenetics

Indexed keywords

6 (2,4 DIFLUOROPHENOXY) 2 (2 HYDROXY 1 METHYLETHYLAMINO) 8 (2 HYDROXY PROPYL) 8H PYRIDOL[2,3 D]PYRIMIDIN 7 ONE; ALDEHYDE OXIDASE; ALDEHYDE OXIDASE 1; ANTIRHEUMATIC AGENT; DRUG METABOLITE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PLACEBO; RECOMBINANT ENZYME; RO 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AOX1 GENE; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENE; GENE CONTROL; GENETIC SCREENING; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ALDEHYDE OXIDASE; ANIMALS; ARTHRITIS, RHEUMATOID; DOGS; FEMALE; HALF-LIFE; HAPLORHINI; HUMANS; LIVER; MALE; MICE; MICE, INBRED STRAINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHARMACOGENETICS; PROTEIN KINASE INHIBITORS; PYRIMIDINONES; RATS; RATS, INBRED BB; SINGLE-BLIND METHOD; SPECIES SPECIFICITY; YOUNG ADULT;

CANIS FAMILIARIS; MURINAE; MUS; RATTUS;

EID: 78650303504     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.8     Document Type: Article

References (39)

1. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006; 7: 165-182.
2. Poggesi I. Predicting human pharmacokinetics from preclinical data. Curr Opin Drug DiscovDevel 2004; 7: 100-111.
3. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004; 14: 1-18.
4. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006; 2: 875-894.
5. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 23: 1008-1021.
6. Casley WL, Menzies JA, Girard M, Larocque L, Mousseau N, Whitehouse LW et al. Differences in caffeine 3-demethylation activity among inbred mouse strains: a comparison of hepatic Cyp1a2 gene expression between two inbred strains. Fundam Appl Toxicol 1997; 40: 228-237.
7. Bernard-Helary K, Ardourel MY, Hevor T, Cloix JF. In vivo and in vitro glycogenic effects of methionine sulfoximine are different in two inbred strains of mice. Brain Res 2002; 929: 147-155.
8. Koster AS, Nieuwenhuis L, Frankhuijzen-Sierevogel AC. Comparison of microsomal drug-metabolizing enzymes in 14 rat inbred strains. Biochem Pharmacol 1989; 38: 759-765.
9. Guo YY, Weller PF, Farrell E, Cheung P, Fitch B, Clark D et al. In silico pharmacogenetics: warfarin metabolism. Nat Biotechnol 2006; 24: 531-536.
10. Guo YY, Liu P, Zhang X, Weller PMM, Wang J, Liao G et al. In vitro and in silico pharmacogenetic analysis in mice. Proc Natl Acad Sci USA 2007; 104: 17735-17740.
11. Liao G, Wang J, Guo J, Allard J, Cheng J, Ng A et al. In silico genetics: identification of a functional element regulating H2-Ea gene expression. Science 2004; 306: 690-695.
12. Wang J, Liao G, Usuka J, Peltz G. Computational genetics: from mouse to man? Trends Genet 2005; 21: 526-532.
13. Wang J, Peltz G. Haplotype-Based Computational Genetic Analysis in Mice. Computational Genetics and Genomics: New Tools for Understanding Disease. Humana Press Inc.: Totowa, New Jersey, 2005. pp 51-70.
14. Wang J, Liao G, Chang J, Nguyen A, Guo J, Chou S et al. Haplotypic Structure of the Mouse Genome. Computational Genetics and Genomics: New Tools for Understanding Disease. Humana Press Inc.: Totowa, New Jersey, 2005. pp 71-83.
15. Liao G, Zhang X, Clark DJ, Peltz G. A genomic 00roadmap00 to 00better00 drugs. Drug Metab Rev 2008; 40: 225-239.
16. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245: R768-R775.
17. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharmacol 1973; 1: 435-461.
18. Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54: 95-101.
19. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary- comparative paradigm. Drug Metab Rev 1984; 15: 1071-1121.
20. Kurosaki M, Demontis S, Barzago MM, Garattini E, Terao M. Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone. Biochem J 1999; 341(Part 1): 71-80.
21. Zheng M, Shafer SS, Liao G, Liu H-H, Peltz G. Computational genetic mapping in mice: 'The Ship has Sailed'. Sci Transl Med 2009; 1: 3ps4.
22. Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos 1990; 18: 190-196.
23. Mathews JM, Dostal LA, Bend JR. Inactivation of rabbit pulmonary cytochrome P-450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole. J Pharmacol Exp Ther 1985; 235: 186-190.
24. Panoutsopoulos GI, Beedham C. Enzymatic oxidation of vanillin, isovanillin and protocatechuic aldehyde with freshly prepared Guinea pig liver slices. Cell Physiol Biochem 2005; 15: 89-98.
25. Klaassen CD. Casarett & Doull's Toxicology: The Basic Science of Poisons. 6th edn. The McGraw-Hill Companies, Inc.: Columbus, OH, 2001.
26. Sugihara K, Kitamura S, Tatsumi K. Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug MetabDispos 1996; 24: 199-202.
27. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, Watabe T. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 1999; 27: 422-428.
28. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23: 229-232.
29. Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995; 23: 251-254.
30. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997; 25: 805-813.
31. Beedham C. Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 1985; 16: 119-156.
32. Gluecksohn-Waelsch S, Greengard P, Quinn GP, Teicher LS. Genetic variations of an oxidase in mammals. J Biol Chem 1967; 242: 1271-1273.
33. Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 2006; 21: 83-98.
34. Itoh K, Maruyama H, Adachi M, Hoshino K, Watanabe N, Tanaka Y. Lack of dimer formation ability in rat strains with low aldehyde oxidase activity. Xenobiotica 2007; 37: 709-716.
35. Itoh K, Maruyama H, Adachi M, Hoshino K, Watanabe N, Tanaka Y. Lack of formation of aldehyde oxidase dimer possibly due to 377G4A nucleotide substitution. Drug Metab Dispos 2007; 35: 1860-1864.
36. Adachi M, Itoh K, Masubuchi A, Watanabe N, Tanaka Y. Construction and expression of mutant cDNAs responsible for genetic polymorphism in aldehyde oxidase in Donryu strain rats. J Biochem Mol Biol 2007; 40: 1021-1027.
37. Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30: 375-384.
38. Wright RM, Clayton DA, Riley MG, McManaman JL, Repine JE. cDNA cloning, sequencing, and characterization of male and female rat liver aldehyde oxidase (rAOX1). Differences in redox status may distinguish male and female forms of hepatic APX. J Biol Chem 1999; 274: 3878-3886.
39. Rettie AE, Fisher MB. Transformation enzymes: oxidative; non-P450. In: Woolf TF (ed). Handbook of Drug Metabolism. Marcel Dekker: New York, New York, 1999. pp 131-151.